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Screening for iron deﬁciency in surgical patients based on
noninvasive zinc protoporphyrin measurements
Christoph Füllenbach,1,† Philipp Stein,2,† Patricia Glaser,1 Chris Triphaus,1 Simone Lindau,1
Suma Choorapoikayil,1 Elke Schmitt,1 Kai Zacharowski,1 Gudrun Hintereder,3 Georg Hennig,4,5
Christian Homann,4,5 Herbert Stepp,4,5 Gabriela H. Spahn,2 Alexander Kaserer ,2 Andreas Schedler,2
Patrick Meybohm ,1,6,‡ and Donat R. Spahn2,‡
BACKGROUND: Approximately every third surgical
patient is anemic. The most common form, iron
deﬁciency anemia, results from persisting iron-deﬁcient
erythropoiesis (IDE). Zinc protoporphyrin (ZnPP) is a
promising parameter for diagnosing IDE, hitherto
requiring blood drawing and laboratory workup.
STUDY DESIGN AND METHODS: Noninvasive ZnPP
(ZnPP-NI) measurements are compared to ZnPP
reference determination of the ZnPP/heme ratio by high-
performance liquid chromatography (ZnPP-HPLC) and the
analytical performance in detecting IDE is evaluated
against traditional iron status parameters (ferritin,
transferrin saturation [TSAT], soluble transferrin receptor–
ferritin index [sTfR-F], soluble transferrin receptor [sTfR]),
likewise measured in blood. The study was conducted at
the University Hospitals of Frankfurt and Zurich.
RESULTS: Limits of agreement between ZnPP-NI and
ZnPP-HPLC measurements for 584 cardiac and
noncardiac surgical patients equaled 19.7 μmol/mol heme
(95% conﬁdence interval, 18.0–21.3; acceptance criteria,
23.2 μmol/mol heme; absolute bias, 0 μmol/mol heme).
Analytical performance for detecting IDE (inferred from
area under the curve receiver operating characteristics) of
parameters measured in blood was: ZnPP-HPLC (0.95),
sTfR (0.92), sTfR-F (0.89), TSAT (0.87), and ferritin (0.67).
Noninvasively measured ZnPP-NI yielded results of 0.90.
CONCLUSION: ZnPP-NI appears well suited for an
initial IDE screening, informing on the state of
erythropoiesis at the point of care without blood drawing
and laboratory analysis. Comparison with a
multiparameter IDE test revealed that ZnPP-NI values of
40 μmol/mol heme or less allows exclusion of IDE,
whereas for 65 μmol/mol heme or greater, IDE is very
likely if other causes of increased values are excluded.
In these cases (77% of our patients) ZnPP-NI may
sufﬁce for a diagnosis, while values in between require
analyses of additional iron status parameters.
ABBREVIATIONS: ACD = anemia of chronic disease; AUCROC = area under
the curve receiver operating characteristics; CRP = C-reactive protein;
IDA = iron deﬁciency anemia; IDE = iron-deﬁcient erythropoiesis;
IL-6 = interleukin-6; LoAs = limits of agreement; MCH = mean corpuscular
hemoglobin; MCV = mean corpuscular volume; ROC = receiver operating
characteristics; sTfR = soluble transferrin receptor; sTfR-F = soluble
transferrin receptor–ferritin index; TSAT = transferrin saturation;
ZnPP = zinc protoporphyrin; ZnPP-NI = noninvasive zinc protoporphyrin;
ZnPP-HPLC = high-performance liquid chromatography zinc
protoporphyrin.
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I
ron is essential for an optimal erythropoiesis. Insufﬁ-
ciency results in iron-deﬁcient erythropoiesis (IDE),
which, if persistent, eventuates in iron deﬁciency ane-
mia (IDA). In surgical patients, of which approxi-
mately one-third suffers from preoperative anemia, 23% to
72% of suboptimal hemoglobin (Hb) concentrations are
associated with a shortage of erythropoietic iron supply.1–3
Preoperative anemia itself is an independent risk factor
for a prolonged hospitalization, a higher need for alloge-
neic blood transfusions and increased morbidity and
mortality.4–6 In iron-deﬁcient patients, iron supplementa-
tion is a potent strategy to increase Hb levels and reduce
transfusion requirements.7–10 Managing preoperative ane-
mia by providing a pragmatic treatment within the often
short time available to ensure optimal surgical preparation
is an integral part of patient blood management, a multi-
modal clinical concept to improve patient safety.11
Diagnosing anemia based on Hb levels is straightfor-
ward, yet only allows identiﬁcation of patients already com-
promised by a reduced hemoglobin mass. Screening for IDE
to provide treatment to patients already or not yet anemic
due to iron deﬁciency, however, is much more challenging
despite a plethora of iron status parameters. This is espe-
cially true when inﬂammation or comorbidities are present.
A proxy highly sensitive for the iron availability during
erythropoiesis is zinc protoporphyrin (ZnPP), primarily for-
ming when iron supply to the erythron is insufﬁcient or
functionally impaired.12–17 In fact, ZnPP has been suggested
to detect inadequate iron supply in different populations16,17
and children.15 Hitherto, however, ZnPP measurements
required blood sampling and, to provide reliable results,
additional washing of erythrocytes.18,19 A novel analytical
technique sets out not only to render cumbersome laboratory
workup obsolete20 but also to enable the noninvasive quanti-
ﬁcation of ZnPP at the point of care without blood sampling
and laboratory analysis.21
In this prospective multicenter study, we compare non-
invasive ZnPP measurements to reference measurements
and evaluate the analytical performance of the novel tech-
nique and of standard iron status parameters to detect IDE
in a heterogeneous cohort of cardiac and noncardiac surgi-
cal patients.
MATERIALS AND METHODS
Study design and patients
This multicenter study was conducted at the University Hos-
pitals of Frankfurt (UKF) and Zurich (USZ) and is registered
as NCT03071497 (UKF) and NCT03231865 (USZ). Ethics
committees at both sites approved the study protocol.
Patients (aged ≥18 y) undergoing major elective cardiac and
noncardiac surgery between March 2017 and April 2018
were included. Recent blood transfusion (<8 wks before
examination), pregnancy, or diagnosis of porphyria were
exclusion criteria. Written informed consent was obtained
from each participant. Blood samples (UKF: 1 × 2.6 mL
ethylenediaminetetraacetic acid tube, 1 x 4 mL serum tube;
USZ: 1 × 2.7 mL ethylenediaminetetraacetic acid tube,
1 × 10 mL serum tube; both Sarstedt AG & Co. KG) for ana-
lyses were collected preoperatively during clinical routine.
Assessments
At both sites, two aliquots of ethylenediaminetetraacetic acid
blood (250 μL each) were stored at −80°C for reference deter-
mination of the ZnPP/heme ratio by high-performance liquid
chromatography (ZnPP-HPLC), as previously described.21
Noninvasive ZnPP measurements (ZnPP-NI) were performed
preoperatively at the study sites by various examiners with
prototype devices (FIDscreen). Before study enrollment, the
prototypes (one at each study site) were calibrated against an
external optical standard, and the relative calibration factor
between the two prototypes was ﬁxed (for detailed descrip-
tion see Appendix S1 and Fig. S1, available as supporting
information in the online version of this paper). The working
principle of the prototypes is described elsewhere.21
At the UKF, red blood cell (RBC) indices (Hb, mean
corpuscular hemoglobin [MCH], mean corpuscular volume
[MCV]) were measured using an analyzer (XN-9000, Sysmex).
An analyzer (Cobas 8000, Roche Diagnostics) was used to mea-
sure serum iron (module c701), serum ferritin (module e602,
electrochemiluminescence immunoassay), serum transferrin
(module c502), soluble transferrin receptor (sTfR; module c502,
Tina-quant Soluble Transferrin Receptor assay), C-reactive pro-
tein (CRP; module c701, latex-enhanced immunoturbidimetry),
and interleukin-6 (IL-6; e602, electrochemiluminescence
immunoassay). At the USZ, RBC indices (Hb, MCH, MCV)
were measured using an analyzer (XE-5000, Sysmex). The
Cobas 8000 was used to measure serum iron (module c502),
serum ferritin (module e801, electrochemiluminescence immu-
noassay), serum transferrin (module c502), CRP, and IL-6
(module e801). sTfR was measured using a nephelometric ana-
lyzer (Atellica Neph 630, Siemens Healthineers, immuno-
nephelometry). Transferrin saturation (TSAT) was calculated
as = (Serum iron [μg/dL] / Serum transferrin [mg/mL]) × 70.9.
sTfR-F index (sTfR-F) was calculated as = sTfR [mg/L] / log
(Serum ferritin) [ng/mL].
Clinical deﬁnitions
Evaluating the analytical performance of iron status param-
eters to detect IDE requires an a priori identiﬁcation of
affected patients. Bone marrow aspiration, the gold standard
to estimate the body iron stores, is highly invasive and not
routinely performed at the study sites. As using a single iron
status parameter for diagnosing IDE might result in an
under- or overestimation of the incidence rate, a multi-
parameter index test was applied.22–24 Patients were
assigned to the “IDE group” if at least two of three parame-
ters (TSAT, sTfR, ZnPP-HPLC) indicated IDE, or the “no
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IDE group” if none or only one parameter was positive. All
three parameters were chosen for the initial identiﬁcation,
as they provide information on the availability of iron for
erythropoiesis.14,25,26 Cutoff values of TSAT (<20%) and sTfR
(women >4.4 mg/L, men >5 mg/L) are inferred from a con-
sensus statement,27 national guidelines,28,29 and recommen-
dations by the manufacturer and central laboratories at
both sites. The cutoff value of ZnPP (>40 μmol/mol heme,
applied for both ZnPP-HPLC and ZnPP-NI) is inferred from
the literature,12,13,16,30 matching recommendations of the
laboratory conducting the reference measurements. Cutoff
values indicating reduced iron stores for ferritin (<100 ng/
mL), MCH (<27 pg), and MCV (<80 fL) are inferred from
recommendations by the central laboratories and the litera-
ture.27 Although a lower ferritin cutoff (<30 ng/mL) is more
speciﬁc for absolute iron deﬁciency,31 we preferred a higher
cutoff (<100 ng/mL) suggested as indicative for low iron
stores in surgical patients.27 The reasoning here is that only
replete iron stores (>100 ng/mL) ensure a supply sufﬁcient
for an optimal perioperative erythropoiesis even during
major surgical blood loss. Furthermore, this cutoff was
suggested as an indicator for iron deﬁciency in nonanemic
patients with various comorbidities (e.g., chronic kidney dis-
ease, inﬂammatory bowel disease).32 Cutoff values of sTfR-F
(women >2.2, men >2.5) were calculated as follows:
women = 4.4 [mg/L] / log(100) [ng/mL]; men = 5 [mg/L] /
log(100) [ng/mL]. To decide upon copresence of inﬂamma-
tion, we used CRP cutoff values greater than 5 mg/dL
and/or IL-6 levels greater than 7 pg/mL, as recommended
by the central laboratories (if both were available, CRP was
preferred). Anemia, deﬁned by the World Health Organiza-
tion as Hb less than 12 g/dL in women and less than 13 g/
dL in men, respectively,33 was not used to divide the study
population for further subgroup analyses, as IDE can be
present irrespective of anemia. Nonetheless, as prevalence
of IDA, anemia of chronic disease (ACD), a combination of
both or other causes of anemia within the study groups
(“no IDE” and “IDE”) might be of interest for some readers,
we used a modiﬁed version of an algorithm published by
Skikne et al.34 (for details see Fig. S2, available as supporting
information in the online version of this paper) to provide
these numbers within the Appendix S1.
Statistical analysis
Because all analyzed parameters were not normally distrib-
uted (Shapiro–Wilk-test; p <0.05 considered signiﬁcant),
data are given as medians (interquartile range [IQR], Q1–
Q3). Accordingly, differences between two groups were
tested with the Mann–Whitney U test (p <0.05 considered
signiﬁcant). To evaluate the analytical performance of iron
status parameters to detect IDE, receiver operating charac-
teristics (ROC) including area under the curve (AUCROC)
and contingency tables were computed based on cutoffs
listed in Clinical Deﬁnitions.
For direct comparison of noninvasive and reference
ZnPP measurements (ZnPP-NI vs. ZnPP-HPLC), noninva-
sive values were scaled to the reference HPLC determina-
tion by a linear ﬁt with zero offset (see Appendix S1 and
Fig. S1, available as supporting information in the online
version of this paper). For quantitative comparison of both
methods, limits of agreement (LoAs) as well as absolute and
relative biases were calculated using the robust τ-estimate
of the differences between the two. The 95% conﬁdence
intervals (CIs) were calculated by bootstrapping. The LoAs
were considered acceptable if they did not exceed the LoAs
of repeated determinations of ZnPP by HPLC by more than
20%. All calculations were done with computer software
(MATLAB R2014b, The MathWorks Inc.), with exception of
the LoAs (95% CI), for which another software (R version
3.2.2, functions scaleTau2, boot, boot.ci) was used.
RESULTS
Initially, 649 patients undergoing major elective surgery were
included, 65 of which were excluded because at least one
measuring parameter was missing (n = 44), there were issues
with the hardware or software of the noninvasive device
(n = 14), the patient had received a blood transfusion less than
8 weeks before examination (n = 6), or for other reasons
(n = 1; Fig. 1). The median age was 65 (IQR, 54–73; range,
18–91) years and 34.8% (n = 203) were female. Included
patients were scheduled for cardiac (n = 260), general
(n = 39), gynecologic (n = 2), hepatopancreatobiliary (n = 68),
maxillofacial (n = 3), plastic (n = 14), rectal (n = 15), thoracic
(n = 7), transplantation (n = 43), trauma (n = 5), upper gastro-
intestinal (n = 40), urological (n = 25), vascular (n = 31), or
other (n = 32) surgery.
The LoAs between noninvasive and HPLC reference
ZnPP measurements for n = 584 patients equaled
19.7 μmol/mol heme (95% CI, 18.0–21.3) with no bias
(Fig. 2). For comparison, LoAs between ZnPP values of
repeated HPLC measurements were 19.3 μmol/mol heme
(95% CI, 17.8–20.6) for 583 patients with an absolute bias of
−2.8 μmol/mol heme and a relative bias of −7.3% (for
Bland–Altman plot see Fig. S3, available as supporting infor-
mation in the online version of this paper). Hence, LoAs
between noninvasive and HPLC reference ZnPP measure-
ments were within the predeﬁned acceptance criteria
(23.2 μmol/mol heme = 1.2 × 19.3 μmol/mol heme).
In total, 447 patients were assigned to the no IDE group
(no [n = 265] or only one [n = 182] parameter indicating
IDE; Fig. 1), in which medians of RBC indices, iron status
parameters, and inﬂammation markers did not exceed or
fall below respective cutoff values (Table 1). Twelve of those
with only one parameter indicating IDE had ferritin values
less than 30 ng/mL. In contrast, medians of RBC indices
(except for MCH and MCV) and iron status parameters in
the IDE group (n = 137), exceeded or were below cutoff
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Fig. 1. Flowchart showing the study population. Parameters (and cutoffs) used for multiparameter index test to detect IDE: transferrin
saturation (<20%), soluble transferrin receptor (>4.4 mg/L in women, >5 mg/L in men), and ZnPP measured with HPLC (>40 μmol/mol
heme). Patients were assigned to the no IDE group, if none or only one index parameter was positive or to the IDE group, if at least two
index parameters were positive. IDE = iron-deﬁcient erythropoiesis. *Blood sample likely contaminated, as it was taken through the
same peripheral venous catheter previously used for intravenous iron supplementation.
Fig. 2. Bland–Altman plots for the comparison of ZnPP measured in blood samples using high-performance liquid chromatography
(ZnPP-HPLC) and noninvasively by ﬂuorescence analysis (ZnPP-NI). (A) gives the complete data set, (B) depicts a magniﬁcation of (A).
Solid blue lines indicate robust limits of agreement (equaling 1.96 times of the robust SD). Bias (equal to zero) is indicated by blue
dashed line. Acceptance criteria are shown in red and are deﬁned as 1.2 times the robust limits of agreement of repeated ZnPP
determinations by HPLC.
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values, consistently indicating iron deﬁciency and IDE,
respectively. The median of CRP (7.9 mg/dL; IQR, 2.0–18.4)
also exceeded cutoff, indicating a higher prevalence of
inﬂammation in this group. Ferritin values of both groups
showed considerable overlap, whereas values of sTfR, ZnPP-
HPLC, and ZnPP-NI allowed a slightly better visual separa-
tion (Fig. 3). For results of additional screening for anemia
(and potential causes) within the study groups based on a
modiﬁed version of an algorithm published elsewhere,34 see
Table S1, available as supporting information in the online
version of this paper.
Iron status parameters differed markedly regarding
their analytical performance to detect IDE (Table 2). For the
total population, overall analytical performance (inferred
from AUCROC) declined from ZnPP-HPLC (0.95), to sTfR
(0.92), to ZnPP-NI (0.90), to sTfR-F (0.89), to TSAT (0.87),
and to ferritin (0.63; for ROC curves see Fig. S4, available as
supporting information in the online version of this paper).
Based on predeﬁned cutoffs (see Clinical Deﬁnitions), ferri-
tin revealed lowest sensitivity (51%) and speciﬁcity (72%).
Highest speciﬁcities were achieved by sTfR (99%) and sTfR-
F (95%), with both accompanied by low sensitivities (61%
for both). Highest equally balanced sensitivity (94%) and
speciﬁcity (87%) were achieved by ZnPP-HPLC. ZnPP-NI
likewise revealed balanced values for sensitivity (81%) and
speciﬁcity (84%). Computed optimal cutoff values for the
TABLE 1. RBC indices, iron status parameters, and markers of inﬂammation for the no IDE group, the IDE group, and
for all patients
Parameter No IDE (n = 447) IDE (n = 137) p value All (n = 584)
Hb (g/dL) 13.8 (12.6-14.8) 11.8 (10.6-13.1) <0.0001 13.5 (12.0-14.6)
MCV (fL) 89.9 (86.7-93.4) 85.0 (81.5-89.8) <0.0001 89.1 (85.3-92.6)
MCH (pg) 30.2 (29.1-31.3) 28.1 (25.7-29.5) <0.0001 29.8 (28.5-31.0)
Ferritin (ng/mL) 173 (90.0-300.0) 93 (29-261) <0.0001 159 (71-296)
TSAT (%) 24.0 (19.5-30.4) 12.1 (8.2-17.0) <0.0001 21.9 (16.0-28.5)
sTfR-F 1.3 (1.0-1.6) 2.5 (1.9-3.8) <0.0001 1.5 (1.1-2.1)
sTfR (mg/L) 2.8 (2.4-3.4) 5.1 (4.0-6.7) <0.0001 3.1 (2.5-4.0)
ZnPP-HPLC (μmol/mol heme) 27.8 (21.6-34.6) 64.3 (47.7-88.1) <0.0001 31.3 (23.2-45.3)
ZnPP-NI (μmol/mol heme) 29.6 (23.2-35.9) 51.9 (42.8-71.6) <0.0001 33.1 (25.2-44.2)
CRP (mg/dL) 3.0 (1.0-7.0) 7.9 (2.0-18.4) <0.0001 3.0 (1.0-8.9)
IL-6 (pg/mL) 3.6 (2.0-7.2) 5.8 (3.5-9.6) 0.044 4.2 (2.1-7.3)
Results are median (IQR). Mann–Whitney U tests comparing parameters between the group of patients with normal (no IDE) and impaired
erythropoiesis (IDE) revealed signiﬁcant differences.
CRP = C-reactive protein; Hb = hemoglobin; IDE = iron-deﬁcient erythropoiesis; IL-6 = interleukin-6; MCH = mean corpuscular hemoglobin;
MCV = mean corpuscular volume; sTfR = soluble transferrin receptor; sTfR-F = soluble transferrin receptor–F index; TSAT = transferrin satura-
tion; ZnPP-HPLC = high-performance liquid chromatography zinc protoporphyrin; ZnPP-NI = noninvasive zinc protoporphyrin.
Fig. 3. Distribution of ferritin, TSAT, sTfR-F, sTfR, ZnPP-HPLC, and ZnPP-NI values in patients with normal (no IDE, n = 447) and iron-
deﬁcient (IDE, n = 137) erythropoiesis. Black horizontal lines depict respective iron deﬁciency cutoff value of each parameter. For sTfR-
F and sTfR, the upper line represents the cutoff for men, the lower one the cutoff for women. Medians are marked by orange crosses.
Colored rectangles envelope patients correctly (green) or falsely (red) assigned to no IDE/IDE group by respective parameters. Note:
ferritin is shown on a logarithmic scale.
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total study population of ferritin (101 ng/mL), TSAT
(19.0%), ZnPP-HPLC (40.0 μmol/mol heme), and ZnPP-NI
(39.6 μmol/mol heme) matched conventional reference
limits, while those computed for sTfR-F (1.7) and sTfR
(3.7 mg/L) remained below. For analytical performance
based on the computed optimal cutoffs see Table S2, avail-
able as supporting information in the online version of this
paper.
To evaluate potential effects of inﬂammation on iron
status parameters, the study population was separated into
four subgroups, based on sTfR levels and probability of
inﬂammation inferred from CRP and IL-6 (Table 3). sTfR
was explicitly chosen as differentiator for the state of eryth-
ropoiesis, as it is suggested to be the parameter least
inﬂuenced by inﬂammation.23,34,35 Corroborating these
ﬁndings, medians of sTfR in the group with normal sTfR dif-
fered only slightly between subgroups with (3.0 mg/L) and
without inﬂammation (2.9 mg/L). For ZnPP-HPLC and
ZnPP-NI, medians were higher in the subgroup with (31.6
and 34.7 μmol/mol heme) compared to the subgroup with-
out inﬂammation (28.3 and 29.6 μmol/mol heme), although
remaining within normal range (≤40 μmol/mol heme). Fer-
ritin and TSAT displayed large differences, with ferritin
levels being higher (201 ng/mL vs. 150 ng/mL) and TSAT
being lower (20.0% vs. 24.1%) in the subgroup with inﬂam-
mation. In the group with elevated sTfR, ferritin was again
higher by approximately 50 ng/mL in the subgroup with
inﬂammation (97 ng/mL vs. 49 ng/mL), whereas TSAT was
again lower in this subgroup (10.8% vs. 11.7%). In the sub-
group with inﬂammation, sTfR, ZnPP-HPLC, and ZnPP-NI
were lower compared to the subgroup without. Aside from
sTfR-F, differences between medians of iron status parame-
ters in the larger group with sTfR normal (n = 496) were sig-
niﬁcant, whereas those in the smaller group with sTfR
elevated (n = 88) were not. Additionally, for all iron status
parameters besides sTfR, a smaller AUCROC for the detection
TABLE 2. Analytical performance of iron status parameters to detect patients with IDE depending on the probability of
copresence of inﬂammation
Ferritin TSAT sTfR-F sTfR ZnPP-HPLC ZnPP-NI
All patients (n = 584)
Sens 51% 89% 61% 61% 94% 81%
Spec 72% 73% 95% 99% 87% 84%
PPV 36% 51% 80% 94% 69% 61%
NPV 83% 96% 89% 89% 98% 94%
False neg 67 15 54 54 8 26
False pos 126 119 21 5 58 72
True neg 321 328 426 442 389 375
True pos 70 122 83 83 219 111
AUCROC 0.63 0.88 0.89 0.92 0.95 0.90
Cutoff 101 ng/mL 19.0% 1.7 3.8 mg/L 40.0 μmol/mol heme 39.6 μmol/mol heme
Patients without inﬂammation (n = 359)
Sens 59% 84% 68% 60% 95% 83%
Spec 70% 79% 96% 99% 88% 88%
PPV 30% 46% 77% 95% 63% 59%
NPV 89% 96% 93% 92% 99% 96%
False neg 26 10 20 25 3 11
False pos 88 62 13 2 35 36
True neg 208 234 283 294 261 260
True pos 37 53 43 38 60 52
AUCROC 0.68 0.87 0.90 0.92 0.96 0.91
Cutoff 85 ng/mL 19.8% 2.1 3.4 mg/L 40.2 μmol/mol heme 39.4 μmol/mol heme
Patients with inﬂammation (n = 225)
Sens 45% 93% 54% 61% 93% 80%
Spec 75% 62% 95% 98% 85% 76%
PPV 46% 55% 83% 94% 75% 62%
NPV 73% 95% 81% 84% 96% 88%
False neg 41 5 34 29 5 15
False pos 38 57 8 3 23 36
True neg 113 94 143 148 128 115
True pos 33 69 40 45 69 59
AUCROC 0.61 0.86 0.88 0.92 0.94 0.86
Cutoff 122 ng/mL 17.1% 1.8 4.0 mg/L 40.0 μmol/mol heme 40.1 μmol/mol heme
Cutoff values used to compute sensitivity (sens), speciﬁcity (spec), positive predictive value (PPV), and negative predictive value (NPV)
were <100 ng/mL for ferritin, <20% for TSAT, >4.4 mg/L for women and >5 mg/L for men for sTfR, >2.2 for women and >2.5 for men for sTfR-F,
and >40 μmol/mol heme for ZnPP-HPLC and ZnPP-NI. Cutoffs for the patient group without inﬂammation were CRP ≤5 mg/dL and IL-
6 ≤7 pg/mL, respectively. Cutoff values displayed in this table were computed using ROC analyses.
AUCROC = area under the curve receiver operating characteristics; IL-6 = interleukin-6; ROC = receiver operating characteristics; sTfR = soluble
transferrin receptor; sTfR-F = soluble transferrin receptor–F index; TSAT = transferrin saturation; ZnPP-HPLC = high-performance liquid chroma-
tography zinc protoporphyrin; ZnPP-NI = noninvasive zinc protoporphyrin.
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of IDE is found in the group of patients with inﬂammation
compared to the group without (Table 2).
DISCUSSION
In many surgical patients, anemia is associated with an
impaired erythropoiesis due to iron deﬁciency,1–3 thus read-
ily treatable if timely diagnosed.7–10 Data of this prospective
multicenter study including 584 cardiac and noncardiac sur-
gical patients demonstrate that a novel noninvasive tech-
nique to measure ZnPP allows detecting IDE with higher
analytical performance compared to the frequently used
iron status parameters ferritin and TSAT.
Of all investigated parameters, ferritin showed the poorest
analytical performance in detecting IDE, for which there are
likely several reasons. First, ferritin is not sensitive to IDE, as it
reﬂects body iron stores. Hence, values below cutoff do not
necessarily indicate IDE, as iron supply might still be adequate
(e.g., through phagocytosis of old erythrocytes), potentially
explaining the high number of 126 false-positive results for
IDE. Second, due to its acute-phase reactant properties and
the high number of patients with copresence of unspeciﬁc
inﬂammation (39%), ferritin values might be falsely “normal”
in many cases, potentially explaining the high number of
67 false-negative results for IDE. Nevertheless, ROC analysis of
ferritin versus IDE yielded a cutoff of 101 ng/mL, matching
the suggested cutoff (100 ng/mL) for this cohort.27 Calcula-
tions based on a lower cutoff (<30 ng/mL) frequently
suggested as most sensitive and speciﬁc test to diagnose abso-
lute iron deﬁciency,31 resulted in a decrease of false-positive
results (n = 12), while false negatives in turn increased
(n = 102). The resulting very high speciﬁcity (97%) and very
low sensitivity (26%) for detecting IDE are likely also caused
by the reasons stated above. Although TSAT clearly out-
performed ferritin in detecting IDE, many patients were still
misclassiﬁed. In simpliﬁed terms, TSAT is the ratio of iron to
transferrin in serum. With the former sensitive to prolonged
overnight fasting and diurnal variations36 and the latter being
an anti–acute-phase protein,37 both may affect TSAT values.
Thus, although ferritin and TSAT are frequently recommended
when screening for iron deﬁciency,27–29 diagnostic results
might be affected by concomitant inﬂammation. A potential
candidate to track erythropoietic iron demand independent
from inﬂammation is sTfR.23,34,35 This is supported by a good
analytical performance even in the presence of inﬂammation
observed here (AUCROC = 0.92 in patients with and without
inﬂammation). The low sensitivity (61%) likely resulted from
the diverging cutoffs recommended by the manufacturer
(>4.4 mg/L women, >5 mg/L men) and optimal values com-
puted by ROC analysis for the studied population (3.8 mg/L).
Computing sTfR-F is suggested to further improve the analyti-
cal sensitivity,34,35 which was not observed here, however,
likely due to the high number of ferritin values affected by
inﬂammation. Despite good analytical results, hospitals may
hesitate with the routine use of sTfR due to analytical costs
(e.g., UKF = 14.57 €; USZ = 77.43 CHF) or different reference
ranges of commercially available reagents.26
Another proxy for iron availability during erythropoiesis
is ZnPP, primarily forming when iron supply to the erythron
is insufﬁcient or functionally impaired and divalent zinc
instead of ferrous iron is incorporated into the heme
scaffolding.12–17 With changes in ZnPP becoming visible
with the formation of new and eryptosis of old erythrocytes,
ZnPP provides long-term information (approx. 3 months)
on the iron status—a fact that needs consideration when
screening patients who recently received allogeneic blood,
as donor ZnPP levels might affect measured values. Data
presented here support the suggested good analytical per-
formance of ZnPP to detect IDE, with ZnPP-HPLC yielding
results at least equaling analytical performance of sTfR in
the entire study population (AUCROC ZnPP-HPLC = 0.95) as
well as within the subgroup of patients suffering from
inﬂammation (AUCROC ZnPP-HPLC = 0.94). Hitherto, ZnPP
TABLE 3. Iron status parameters in dependence on probability of inﬂammation
Parameter
sTfR normal (n = 496) sTfR elevated (n = 88)
No inﬂammation
(n = 319)
Inﬂammation
(n = 177) p value
No inﬂammation
(n = 40)
Inﬂammation
(n = 48) p value
Ferritin (ng/mL) 150 (79-266) 201 (94-358) 0.0034 49 (21-198) 97 (31-321) 0.1
TSAT (%) 24.1 (19.2-30.2) 20.0 (15.0-28.0) <0.0001 11.7 (7.1-21.8) 10.8 (7.0-16.8) 0.38
sTfR-F 1.4 (1.0-1.7) 1.3 (1.0-1.8) 0.67 3.4 (2.6-5.6) 2.9 (2.2-4.0) 0.09
sTfR (mg/L) 2.9 (2.4-3.4) 3.0 (2.5-3.8) 0.02 5.9 (5.4-7.3) 5.7 (5.0-7.3) 0.44
ZnPP-HPLC (μmol/mol heme) 28.3 (21.5-36.3) 31.6 (23.9-42.6) 0.0011 69.5 (49.7-96.6) 65.1 (46.6-97.9) 0.80
ZnPP-NI (μmol/mol heme) 29.6 (23.3-36.1) 34.7 (26.1-45.0) 0.0004 57.7 (46.2-74.1) 50.4 (39.9-84.4) 0.66
CRP (mg/dL) 1.0 (1.0-2.2) 10.5 (6.5-24.0) <0.0001 1.7 (1.0-2.5) 12.6 (9.5-34.9) <0.0001
IL-6 (pg/mL) 3.0 (1.5-4.1) 12.9 (8.7-16.5) <0.0001 5.2 (3.1-6.0) 14.0 (8.2-18.0) 0.0003
Cutoffs for “sTfR normal” were ≤4.4 mg/L in women and ≤5 mg/L in men. Cutoffs for “no inﬂammation” were CRP ≤5 mg/dL and IL-6 ≤7 pg/mL,
respectively. Results are median (IQR). In the patient group with normal sTfR values, Mann–Whitney U tests revealed signiﬁcant differences in
the medians of all parameters, expect the sTfR-F index, between the subgroup of patients with and without inﬂammation. In the group of patients
with elevated sTfR values, there were no statistical differences for the medians of all parameters, expect for CRP and IL-6, between the sub-
group of patients with and without inﬂammation.
CRP = C-reactive protein; IL-6 = interleukin-6; sTfR = soluble transferrin receptor; sTfR-F = soluble transferrin receptor–F index; TSAT = transfer-
rin saturation; ZnPP-HPLC = high-performance liquid chromatography zinc protoporphyrin; ZnPP-NI = noninvasive zinc protoporphyrin.
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is rarely found in clinical routines, potentially because
results of the most prevalent analytical technique (front-face
ﬂuorometry on a drop of blood) can be falsely increased by
simultaneously detecting background signals of other
ﬂuorophores (e.g., bilirubin) if blood samples are measured
unwashed.18,19 A novel analytical technique circumvents
these issues by means of dual-wavelength excitation allow-
ing the noninvasive quantiﬁcation of ZnPP at the point of
care without extensive laboratory equipment or blood sam-
pling.20,21 An optical ﬁber probe illuminates the patient’s
lower lip and acquires ﬂuorescence emission intensity of
erythrocyte bound ZnPP, based on which information on
the erythropoietic iron supply is available within minutes.21
Corroborating previous ﬁndings, the LoAs between ZnPP-
HPLC reference measurements in blood and ZnPP-NI in the
more heterogeneous collective studied here (19.7 μmol/mol
heme) equaled results of the group of postpartum women
of a previous study (19.0 μmol/mol heme).21 Analytical per-
formance of ZnPP-NI (AUCROC = 0.90) in detecting IDE
compared well to standard iron status parameters measured
in blood (AUCROC of ZnPP-HPLC = 0.95; sTfR = 0.92; sTfR-
F = 0.89; TSAT = 0.87; ferritin = 0.62). When analysis was
focused on patients with high probability of inﬂammation,
analytical performance of ZnPP-NI to detect IDE remained
good (AUCROC = 0.86). However, in iron-replete patients
(based on sTfR), ZnPP-NI values were increased in the sub-
group with higher probability of inﬂammation (34.7
vs. 29.6 μmol/mol heme, p <0.05; Table 3). This might partly
be explained by ZnPP not only being increased by absolute
iron deﬁciency but also by impaired iron bioavailability dur-
ing ACD, including chronic inﬂammation.13 With differ-
ences between both subgroups being relatively small and
both medians remaining below cutoff, however, a major
impact of chronic inﬂammatory disorders on the measured
ZnPP-NI in the studied cohort seems rather unlikely. In iron-
replete patients, raised ZnPP values can also result from lead
exposure or genetic/acquired disorders including
myelodysplastic syndrome,30 α- and β-thalassemia traits,38
hemoglobinopathies, porphyrias, and sideroblastic/inherited
microcytic anemias,21 with strongly varying prevalence
depending on the patient group in focus. When these diagno-
ses are known, other, less affected iron status parameters
should be consulted. Especially in populations with patients
from Africa, the Mediterranean, and Southeast Asia, mild and
undiagnosed hemoglobinopathies should be considered.
To minimize risk of potential misdiagnosis due to
slightly elevated values when using ZnPP-NI as initial
screening parameter for IDE (e.g., as part of preoperative
anemia management programs) we suggest a transition
zone, in which ZnPP-NI diagnoses are largely indeﬁnite and
should thus be veriﬁed by other parameters (TSAT and
sTfR). The lower limit of this transition zone (40 μmol/mol
heme) represents the mean cutoff calculated by ROC analy-
sis (corresponding well with the literature12,13,16,30). A rea-
sonable deﬁnition of the upper limit is 65 μmol/mol heme,
including more than 95% of false-positive identiﬁed patients
in the transition zone. Values outside of the transition zone
are either indicative for IDE unlikely (≤40 μmol/mol heme)
or IDE likely (≥65 μmol/mol heme). When putting this algo-
rithm to a test in the heterogeneous study population, diag-
noses based on noninvasive ZnPP values outside the
transition zone were largely corroborated by results of the
multiparameter index test (Fig. 4). In fact, of the 401 patients
with ZnPP-NI of 40 μmol/mol heme or less, 94% (n = 375)
were likewise diagnosed as not suffering from IDE by the
multiparameter index test (i.e., part of the “no IDE” group),
whereas for the 47 patients with ZnPP-NI of 65 μmol/mol
heme or greater, 96% (n = 45) were likewise classiﬁed as
suffering from IDE (IDE group). That implies that in 77%
(n = 448) of the study population, additional blood drawings
and laboratory work to diagnose IDE might have been
unnecessary, as largely coinciding results can be achieved
noninvasively, quicker, and at the point of care. ZnPP-NI
values in the transition zone (>40 and <65 μmol/mol heme,
n = 136; 23%) were clearly indeﬁnite regarding IDE (no IDE,
n = 70; 51% vs. IDE, n = 66; 49%, following multiparameter
test) and should thus be veriﬁed by other parameters (TSAT
and sTfR). We furthermore emphasize that when treatment
is provided for IDE diagnosed by ZnPP-NI, potential con-
founding factors must be excluded.
This study has some limitations that should be men-
tioned. First, patients who received iron supplementation less
than 8 weeks before examination were not excluded. With
iron status parameters naturally changing following iron sup-
plementation and some responding earlier than others, this
might have affected the presented results. With the low num-
ber of patients potentially affected by intravenous iron sup-
plementation (UKF = 6; USZ = 16), the impact on the overall
cohort is presumably small. Second, no details on com-
orbidities or chronic underlying diseases besides inﬂamma-
tion are provided. Third, no in-depth differential diagnosis of
patients suffering from IDA or ACD was performed for the
study population, which is part of an optimal patient blood
management. Fourth, the suggested IDE screening algorithm
was tested on the same population used for its compilation
and not on an independent validation cohort. Hence, future
studies should test if the cutoffs suggested in the algorithm
remain valid in other populations.
In conclusion, ZnPP-NI measurements allowed for
detecting IDE in a large cohort of surgical patients. Analyti-
cal performance with and without concomitant inﬂamma-
tion was higher compared to the frequently used
parameters ferritin and TSAT measured in blood. Contra-
sting traditional parameters, the novel technique provides
point of care information on the erythropoiesis within
minutes without the need for blood sampling and labora-
tory analyses. An additional advantage of the new technique
is the low associated costs per measurement, as only a dis-
posable plastic cover employed for hygienic reasons with
manufacturing costs less than US$1 is needed, but no
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chemicals or biologic assays. Hence, if other causes of
increased values either have a low prevalence in the popu-
lation in focus or can be excluded (e.g., via patient history),
ZnPP-NI measurements seem well suited as an initial
screening parameter for IDE. Potential ﬁelds of application
might be the routine screening of surgical patients as part of
patient blood management programs, out-of-hospital medi-
cal ofﬁces, or resource-limited settings.
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